Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma (NAMS) Income from Continuing Operations (2023 - 2025)

NewAmsterdam Pharma's Income from Continuing Operations history spans 3 years, with the latest figure at 71093000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 177.13% year-over-year to 71093000.0; the TTM value through Dec 2025 reached 57803000.0, up 76.07%, while the annual FY2025 figure was 57803000.0, 76.07% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 71093000.0 at NewAmsterdam Pharma, up from 72005000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 71093000.0 in Q4 2025 and bottomed at 93767000.0 in Q1 2024.
  • The 3-year median for Income from Continuing Operations is 39267000.0 (2024), against an average of 33913083.33.
  • The largest annual shift saw Income from Continuing Operations tumbled 563.5% in 2024 before it soared 177.13% in 2025.
  • A 3-year view of Income from Continuing Operations shows it stood at 19887000.0 in 2023, then crashed by 563.5% to 92177000.0 in 2024, then soared by 177.13% to 71093000.0 in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Income from Continuing Operations are 71093000.0 (Q4 2025), 72005000.0 (Q3 2025), and 17364000.0 (Q2 2025).